Structural Characterization of the Aggregates of Gemtuzumab Ozogamicin
Sign Up to like & getrecommendations! Published in 2019 at "ACS Omega"
DOI: 10.1021/acsomega.8b03627
Abstract: The preparation of antibody drug conjugates (ADCs), particularly those containing hydrophobic payloads, may promote aggregate formation. The aggregate (high molecular mass species, HMMS) is an impurity that must be controlled in the final drug substance… read more here.
Keywords: preparation; structural characterization; gemtuzumab ozogamicin; characterization aggregates ... See more keywords
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-020-01207-4
Abstract: The phase 3 ALFA-0701 trial demonstrated improved outcomes with fractionated-dose gemtuzumab ozogamicin (GO) combined with standard chemotherapy vs. standard chemotherapy alone in adults with de novo acute myeloid leukemia (AML). We examined post-transplant outcomes and… read more here.
Keywords: chemotherapy; myeloid leukemia; gemtuzumab ozogamicin; standard chemotherapy ... See more keywords
Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of pediatric hematology/oncology"
DOI: 10.1097/mph.0000000000002404
Abstract: There is no established treatment for patients with acute promyelocytic leukemia (APL) refractory to targeted therapies with all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). We report here a case of an 8-month-old girl with… read more here.
Keywords: blood transplantation; gemtuzumab ozogamicin; promyelocytic leukemia; unrelated cord ... See more keywords
Single‐dose (4.5 mg/m2) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18203
Abstract: Despite major therapeutic improvements, children with relapsed/refractory Acute Myeloid Leukaemia still have poor outcomes and overall survival does not exceed 40%. New treatments are required to improve their outcome; Gemtuzumab ozogamicin (GO), an anti‐CD33 immunoconjugate… read more here.
Keywords: single dose; gemtuzumab ozogamicin; relapsed refractory; combination ... See more keywords
Abstract CT224: Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2021-ct224
Abstract: Background:AML is predominantly a disease of the elderly, yet outcomes remain dismal, particularly for relapsed/refractory (R/R) AML patients (pts). Gemtuzumab Ozogamicin (GO) is a monoclonal antibody targeting CD33–commonly expressed on AML blasts, and, critically, AML… read more here.
Keywords: gemtuzumab ozogamicin; cancer; study; relapsed refractory ... See more keywords
Gemtuzumab Ozogamicin Treatment Results in Decreased Proliferation and Differentiation of Human Megakaryocytes but Does Not Inhibit Mature Platelet Function
Sign Up to like & getrecommendations! Published in 2022 at "Toxicologic Pathology"
DOI: 10.1177/01926233221129202
Abstract: Mylotarg (Gemtuzumab ozogamicin [GO]), an antibody drug conjugate comprising a CD33-directed antibody linked to calicheamicin, is approved for use in certain acute myeloid leukemia patients. Following reports of prolonged thrombocytopenia and hemorrhagic events in a… read more here.
Keywords: platelet; treatment; gemtuzumab ozogamicin; differentiation human ... See more keywords
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207231154708
Abstract: Gemtuzumab-ozogamicin (GO) is an antibody-drug conjugate (ADC) in which a monoclonal antibody targeting CD33 is covalently linked to the toxin calicheamicin. GO was initially approved by the United States Food and Drug Administration (FDA) for… read more here.
Keywords: myeloid leukemia; treatment; gemtuzumab ozogamicin; acute myeloid ... See more keywords
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.20.03048
Abstract: PURPOSE We investigated the impact of the CD33-targeted agent gemtuzumab ozogamicin (GO) on survival in pediatric patients with KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) enrolled in the Children's Oncology Group trial AAML0531 (NCT01407757). METHODS Patients… read more here.
Keywords: kmt2a aml; free survival; gemtuzumab ozogamicin; risk ... See more keywords
Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin
Sign Up to like & getrecommendations! Published in 2023 at "OncoTargets and Therapy"
DOI: 10.2147/ott.s263829
Abstract: Abstract Although survival in pediatric acute myeloid leukemia (AML) has increased considerably over the past decades, refractory disease and relapse rates remain high. Refractory and relapsed disease are difficult to treat, with overall survival rates… read more here.
Keywords: myeloid leukemia; gemtuzumab ozogamicin; clinical value; acute myeloid ... See more keywords
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group
Sign Up to like & getrecommendations! Published in 2018 at "Haematologica"
DOI: 10.3324/haematol.2018.191841
Abstract: Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia (AML) have poor survival. We evaluated gemtuzumab ozogamicin (CD33-targeted drug) used on a compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid… read more here.
Keywords: myeloid leukemia; gemtuzumab ozogamicin; children relapsed; acute myeloid ... See more keywords
Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14215253
Abstract: Tyrosine kinase inhibitors (TKI) have revolutionised the treatment of CML. However, TKI do not eliminate the leukaemia stem cells (LSC), which can reinitiate the disease. Thus, finding new therapeutic targets in CML LSC is key… read more here.
Keywords: gemtuzumab ozogamicin; cml; tyrosine kinase; gene expression ... See more keywords